Oruka Therapeutics (NASDAQ:ORKA) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a “buy” rating on the stock.

ORKA has been the topic of several other reports. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $41.25.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $26.47 on Monday. Oruka Therapeutics has a 52 week low of $18.72 and a 52 week high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.